Chromatine/Épigénétique
Les inhibiteurs de la chromatine/épigénétique sont des composés qui modulent la structure et la fonction de la chromatine ou interfèrent avec les modifications épigénétiques, telles que la méthylation de l'ADN et la modification des histones. Ces inhibiteurs sont des outils essentiels pour étudier la régulation de l'expression génique et le rôle de l'épigénétique dans des maladies telles que le cancer, les troubles neurologiques et les anomalies du développement. En ciblant les processus épigénétiques, ces inhibiteurs peuvent modifier les schémas d'expression génique et offrir de nouvelles perspectives thérapeutiques. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de la chromatine/épigénétique de haute qualité pour soutenir vos recherches en biologie moléculaire, génétique et épigénétique.
Sous-catégories appartenant à la catégorie "Chromatine/Épigénétique"
2235 produits trouvés pour "Chromatine/Épigénétique"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
KCL-440
CAS :<p>RS 57639 is a bioactive chemical.</p>Formule :C18H18N2O2Couleur et forme :SolidMasse moléculaire :294.35BPTF-IN-BZ1
<p>BPTF-IN-BZ1 is a BPTF inhibitor that possesses a high potency with a Kd of 6.3 nM.</p>Formule :C13H15ClN4OCouleur et forme :SolidMasse moléculaire :278.74XY153
<p>XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.</p>Formule :C33H34FN3O4Couleur et forme :SolidMasse moléculaire :555.64JAK2 JH2 binder-1
CAS :<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62Azaphilone-9
CAS :<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Formule :C21H23BrO5Couleur et forme :SolidMasse moléculaire :435.3115:0 PG sodium
CAS :<p>15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.</p>Formule :C36H70NaO10PCouleur et forme :SolidMasse moléculaire :716.90PRMT5-IN-3
CAS :<p>PRMT5-IN-3 is a PRMT5 inhibitor.PRMT5-IN-3 is a combined DNA damaging agent that is synthetically lethal to tumor cells.</p>Formule :C22H23F3N4O3Couleur et forme :SolidMasse moléculaire :448.44GDC-9918
CAS :<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46P300-IN-4
<p>P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.</p>Formule :C29H28ClIN4O5Couleur et forme :SolidMasse moléculaire :674.91Tyk2-IN-20
CAS :<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formule :C24H25N7O2Couleur et forme :SolidMasse moléculaire :443.50ROPA
CAS :<p>ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.</p>Formule :C28H32O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.55CBP/p300-IN-18
<p>CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).</p>Formule :C25H27FN4O3Couleur et forme :SolidMasse moléculaire :450.51BET-IN-27
CAS :<p>BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.</p>Formule :C21H23N5O3SCouleur et forme :SolidMasse moléculaire :425.5HDAC/Top-IN-1
CAS :<p>HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.</p>Formule :C29H25FN4O4Couleur et forme :SolidMasse moléculaire :512.53JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formule :C20H15ClF3N3OSCouleur et forme :SolidMasse moléculaire :437.87BBC0403
CAS :<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Formule :C21H22N2O5Degré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :382.41JAK2-IN-11
CAS :<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Formule :C19H25N3O5SCouleur et forme :SolidMasse moléculaire :407.48(R)-9b
CAS :<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formule :C20H27ClN6OCouleur et forme :SolidMasse moléculaire :402.92PARP1-IN-30
CAS :<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>Formule :C14H12ClNO4SCouleur et forme :SolidMasse moléculaire :325.77KSQ-4279 (gentisate)
CAS :<p>KSQ-4279 (gentisate) (Compound Formula I) serves as an effective inhibitor of USP1 and a selective inhibitor of PARP1. This compound shows promise for use in cancer research.</p>Formule :C34H31F3N8O5Couleur et forme :SolidMasse moléculaire :688.66HIF-1/2α-IN-1
<p>HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.</p>Formule :C17H16N6O4Couleur et forme :SolidMasse moléculaire :368.35(3S,4R)-Tofacitinib
CAS :<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37W4275
CAS :<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Formule :C25H36N6O3Couleur et forme :SolidMasse moléculaire :468.59GSK789
CAS :<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Formule :C26H33N5O3Couleur et forme :SolidMasse moléculaire :463.57PARP10/15-IN-1
<p>PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].</p>Formule :C13H10N2O3SCouleur et forme :SolidMasse moléculaire :274.3PAD-IN-2
CAS :<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Formule :C27H28ClN5O2Couleur et forme :SolidMasse moléculaire :490RK-582
CAS :<p>RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.</p>Formule :C27H35FN6O3Couleur et forme :SolidMasse moléculaire :510.6HDAC1-IN-8
CAS :<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Formule :C22H24N2O4Couleur et forme :SolidMasse moléculaire :380.437HDAC/HSP90-IN-4
<p>HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.</p>Formule :C20H23N3O6Couleur et forme :SolidMasse moléculaire :401.15869TDI-015051
CAS :<p>TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.</p>Formule :C22H22FN5O4SCouleur et forme :SolidMasse moléculaire :471.505(Rac)-RG108
CAS :<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Formule :C19H14N2O4Couleur et forme :SolidMasse moléculaire :334.326JAK3 covalent inhibitor-1
CAS :<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47AZ0108
CAS :<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Formule :C24H20F4N6O2Couleur et forme :SolidMasse moléculaire :500.45Dot1L-IN-1
CAS :<p>The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.</p>Formule :C32H36ClN9O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :646.21PARP14 inhibitor 1
CAS :<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Formule :C23H27FN4O3Couleur et forme :SolidMasse moléculaire :426.484LSD1/2-IN-3
<p>LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.</p>Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07G-631
CAS :<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Formule :C19H22F2N6O3Couleur et forme :SolidMasse moléculaire :420.41AJI-214
CAS :<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H13ClFN5OCouleur et forme :SolidMasse moléculaire :357.77AZ13824374
<p>AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.</p>Formule :C30H39FN8O2Couleur et forme :SolidMasse moléculaire :562.68LSD1-IN-13 hydrochloride
CAS :<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Formule :C23H30ClN3O2SCouleur et forme :SolidMasse moléculaire :448.02LSD1-IN-35
CAS :<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Formule :C25H26N4O2SCouleur et forme :SolidMasse moléculaire :446.57SMARCA2/4-ligand-5
CAS :<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Formule :C20H13ClN4O3Couleur et forme :SolidMasse moléculaire :392.795PARP1-IN-29
CAS :<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Formule :C18H16FN3O2Couleur et forme :SolidMasse moléculaire :325.34LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Formule :C20H18N2OSCouleur et forme :SolidMasse moléculaire :334.43TY-011
CAS :<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Formule :C18H16ClN5Couleur et forme :SolidMasse moléculaire :337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Formule :C18H18F2N6O3Couleur et forme :SolidMasse moléculaire :404.37Menin-MLL inhibitor 4
CAS :<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Formule :C32H38FN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :587.69KAT6A-IN-2
CAS :<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Formule :C23H29N5O5SCouleur et forme :SolidMasse moléculaire :487.57AMI-408
CAS :<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Formule :C20H13Cl2N6NaO5SCouleur et forme :SolidMasse moléculaire :543.32KAT6A-IN-1
CAS :<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Formule :C23H27N5O5SCouleur et forme :SolidMasse moléculaire :485.56HLCL-61
CAS :<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Formule :C23H24N2OCouleur et forme :SolidMasse moléculaire :344.45LSD1-IN-16
<p>LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.</p>Formule :C20H18N2OSCouleur et forme :SolidMasse moléculaire :334.43Bromodomain inhibitor-13
CAS :<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.43CP-352664
CAS :<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36SMARCA2-IN-2
CAS :<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Formule :C16H17N3Couleur et forme :SolidMasse moléculaire :251.33AJI-100
CAS :<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32PFI-6-COOH
CAS :<p>PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.</p>Formule :C23H21N3O6Couleur et forme :SolidMasse moléculaire :435.43NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Formule :C22H28N2O3Couleur et forme :SolidMasse moléculaire :368.47cis-4-Br-2,5-F2-PCPA
<p>cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.</p>Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07YLIU-4-105-1
CAS :<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formule :C32H34F3N7O2Couleur et forme :SolidMasse moléculaire :605.65Cenacitinib
CAS :<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40CBP/p300-IN-2
CAS :<p>CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).</p>Formule :C27H29F2N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :521.56PRMT5-IN-1
CAS :<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Formule :C19H19ClN4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :418.83PARP1/2-IN-4
CAS :<p>PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.</p>Formule :C23H30FN5O6Couleur et forme :SolidMasse moléculaire :491.51LSD1/HDAC-IN-1
CAS :<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Formule :C18H18N2O4SCouleur et forme :SolidMasse moléculaire :358.41DCHC
CAS :<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Formule :C15H8Cl2O3Couleur et forme :SolidMasse moléculaire :307.128SCR-7952
CAS :<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Formule :C19H15ClN4OCouleur et forme :SolidMasse moléculaire :350.80XP-524
CAS :<p>XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.</p>Formule :C30H28N6O3SCouleur et forme :SolidMasse moléculaire :552.65PARP14 inhibitor 2
CAS :<p>PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.</p>Formule :C25H32FN3O4SCouleur et forme :SolidMasse moléculaire :489.60MS8815
CAS :<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Formule :C65H87N9O8SCouleur et forme :SolidMasse moléculaire :1154.51PF-06263276
CAS :<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63BET-IN-6
CAS :<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Formule :C22H20N2O6SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.47PRMT5-IN-19
<p>PRMT5-IN-19 is a potent, selective PRMT5 inhibitor with IC50 of 23.9 nM and 47 nM, showing anti-cancer activity by inducing apoptosis.</p>Formule :C25H24N4OCouleur et forme :SolidMasse moléculaire :396.48Itareparib
CAS :<p>Itareparib is a PARP inhibitor with demonstrated antitumor activity.</p>Formule :C20H26FN3O2Couleur et forme :SolidMasse moléculaire :359.438HIF-1α-IN-4
<p>HIF-1α-IN-4 is an inhibitor of HIF-1α with IC50 of 24 nM in HEK293T cells which has potential antitumor effects.</p>Formule :C16H12N2O3Couleur et forme :SolidMasse moléculaire :280.28HIF-2α-IN-7
CAS :<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Formule :C18H9F6NO2Couleur et forme :SolidMasse moléculaire :385.26TYK2 ligand 2
CAS :<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458(1-Nitroethene-1,2-diyl)dibenzene
CAS :<p>(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.</p>Formule :C14H11NO2Couleur et forme :SolidMasse moléculaire :225.24Trichostatin A S-isomer
CAS :<p>Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.</p>Formule :C17H22N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :302.37OM-153
CAS :<p>OM-153 blocks tankyrase 1 (IC50: 13 nM) and 2 (IC50: 2 nM), stifling WNT signaling and COLO 320DM cell growth.</p>Formule :C28H24FN7O2Couleur et forme :SolidMasse moléculaire :509.53CM-414
CAS :<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Formule :C23H29N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.51RL5a
CAS :<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Formule :C17H19N3OCouleur et forme :SolidMasse moléculaire :281.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37HDAC-IN-47
<p>HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.</p>Formule :C17H20BrN3O4Couleur et forme :SolidMasse moléculaire :410.26JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35HDAC8-IN-2
<p>HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.</p>Formule :C21H16N2O5Couleur et forme :SolidMasse moléculaire :376.36Enzomenib
CAS :<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Formule :C33H43FN6O3Couleur et forme :SolidMasse moléculaire :590.73MI-1481
CAS :<p>MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.</p>Formule :C29H30F3N7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :597.65HDAC3-IN-3
CAS :<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Formule :C26H22N4O2Couleur et forme :SolidMasse moléculaire :422.48WW437
<p>WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.</p>Formule :C23H27N5O4Couleur et forme :SolidMasse moléculaire :437.49MMSET-IN-1
CAS :<p>MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .</p>Formule :C18H29N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :423.47Equisetin
CAS :<p>Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.</p>Formule :C22H31NO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :373.49PAD4-IN-5
CAS :<p>PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).</p>Formule :C34H41N7O3Couleur et forme :SolidMasse moléculaire :595.734LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Formule :C31H40N6O2Couleur et forme :SolidMasse moléculaire :528.69(2S,3R)-LP99
CAS :<p>(2S,3R)-LP99 is a less active enantiomer of LP99.</p>Formule :C26H30ClN3O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :516.05HDAC-IN-32
<p>HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.</p>Formule :C20H23N3O3Couleur et forme :SolidMasse moléculaire :353.41AFM-30a hydrochloride
<p>AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.</p>Formule :C24H28ClFN6O3Couleur et forme :SolidMasse moléculaire :502.97GSK3368715
CAS :<p>GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s</p>Formule :C20H38N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :366.54FT001
CAS :<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Formule :C25H29N3O4SDegré de pureté :99.9%Couleur et forme :SolidMasse moléculaire :467.58
